ProShares UltraShort NASDAQ Biotechnology
11 hedge funds and large institutions have $3.34M invested in ProShares UltraShort NASDAQ Biotechnology in 2020 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 0 closing their positions.
38% more funds holding
Funds holding: 8 → 11 (+3)
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
24% more capital invested
Capital invested by funds: $2.7M → $3.34M (+$639K)
1.01% more ownership
Funds ownership: 1.58% → 2.59% (+1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$663K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$482K |
| 3 |
HF
HRT Financial
New York
|
+$367K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$185K |
| 5 |
Morgan Stanley
New York
|
+$99.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
WealthSource Partners
San Luis Obispo,
California
|
-$971K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$433K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$21.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HF
1
HRT Financial
New York
| $787K | +$367K | +3,213 | +86% |
|
|
2
Citadel Advisors
Miami,
Florida
| $769K | -$433K | -3,794 | -36% |
|
|
3
Jane Street
New York
| $655K | +$663K | +5,807 | New |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $478K | +$482K | +4,223 | New |
|
|
WP
5
WealthSource Partners
San Luis Obispo,
California
| $212K | -$971K | -8,500 | -82% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $186K | +$185K | +1,621 | +6,235% |
|
|
7
Morgan Stanley
New York
| $108K | +$99.5K | +871 | +979% |
|
8
Simplex Trading
Chicago,
Illinois
| $102K | +$96.2K | +842 | +1,238% |
|
|
CG
9
Cutler Group
San Francisco,
California
| $28K | +$28.6K | +250 | New |
|
|
10
UBS Group
Zurich,
Switzerland
| $7K | -$21.2K | -186 | -75% |
|
11
Citigroup
New York
| $5K | – | – | – |
|
BIS Hedge Fund Activity: Q1 2020 in Review
11 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q1 2020, worth a combined $3.34M — up 24% from $2.7M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BIS positions and 0 closed out — a net gain of 3 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $663K. The largest seller was WealthSource Partners, cutting an estimated $971K.
- 11 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q1 2020, up from 8 in Q4 2019.
- Funds reported $3.34M of ProShares UltraShort NASDAQ Biotechnology stock for Q1 2020, up 24% quarter-over-quarter.
- 3 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q1 2020 and 0 closed out, a net change of +3 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q1 2020 was Jane Street, an estimated $663K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q1 2020 was WealthSource Partners, an estimated $971K sold.
Based on aggregated 13F filings for Q1 2020.